

FOURTH EDITION

# PRINCIPLES OF TOXICOLOGY

ENVIRONMENTAL AND  
INDUSTRIAL APPLICATIONS

EDITED BY

STEPHEN M. ROBERTS | ROBERT C. JAMES  
AND PHILLIP L. WILLIAMS



WILEY

# Table of Contents

[Cover](#)

[TITLE PAGE](#)

[COPYRIGHT](#)

[LIST OF CONTRIBUTORS](#)

[PREFACE](#)

[1 GENERAL PRINCIPLES OF TOXICOLOGY](#)

[1.1 BASIC DEFINITIONS AND TERMINOLOGY](#)

[1.2 TOXICOLOGY: A DIVERSE SCIENCE WITH TWO BASIC GOALS](#)

[1.3 THE HAZARD IDENTIFICATION FUNCTION](#)

[1.4 THE DOSE-RESPONSE/RISK ASSESSMENT FUNCTION](#)

[1.5 HOW DOSE-RESPONSE DATA CAN BE USED](#)

[1.6 AVOIDING INCORRECT CONCLUSIONS FROM DOSE-RESPONSE AND HAZARD IDENTIFICATION DATA](#)

[1.7 ADDITIONAL FACTORS INFLUENCING HAZARD IDENTIFICATION AND DOSE-RESPONSE DATA](#)

[1.8 EVIDENCE-BASED TOXICOLOGY](#)

[1.9 SUMMARY](#)

[REFERENCES AND SUGGESTED READING](#)

[2 XENOBIOTIC ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION](#)

[2.1 ABSORPTION](#)

[2.2 DISTRIBUTION](#)

[2.3 METABOLISM](#)

2.4 EXCRETION

2.5 SUMMARY

REFERENCES AND SUGGESTED READING

### 3 TOXICOKINETICS

3.1 INTRODUCTION

3.2 TOXICOKINETIC MODELING  
FUNDAMENTALS

3.3 APPLICATIONS OF TOXICOKINETICS

3.4 CASE STUDY: TOXICOKINETICS OF DIBUTYL  
PHTHALATE

3.5 TOXICOKINETICS IN THE FUTURE

3.6 SUMMARY

REFERENCES AND SUGGESTED READING

### 4 REGULATORY TOXICOLOGY

4.1 THE “ALPHABET SOUP” THAT IS  
REGULATION

4.2 STANDARDS THAT WE LIVE BY

4.3 REGISTRATION OF CHEMICALS AND  
PRODUCTS IN THE US

4.4 REGISTRATION OF CHEMICALS, NON-US  
REGULATIONS

4.5 REGULATIONS OF NANOMATERIALS

4.6 DESIGNING AND CONDUCTING STUDIES

4.7 GUIDELINES AND GUIDANCE DOCUMENTS

4.8 COMMUNICATING HAZARDS AND SETTING  
SAFE LEVELS

4.9 SUMMARY

REFERENCES AND SUGGESTED READING

NOTES

### 5 ALTERNATIVE METHODS IN TOXICITY TESTING



5.1 INTRODUCTION TO ALTERNATIVE METHODS

5.2 RATIONALE FOR ALTERNATIVE METHOD DEVELOPMENT AND UTILIZATION IN TOXICITY TESTING

5.3 ALTERNATIVE METHODS

5.4 CHEMICAL REGULATIONS AND ALTERNATIVE-TO-ANIMAL TOXICITY TESTING METHODS

5.5 SUMMARY

REFERENCES AND SUGGESTED READING

6 COMPUTATIONAL TOXICOLOGY

6.1 DATA RELEVANT TO COMPUTATIONAL TOXICOLOGY APPLICATIONS

6.2 DATA, DATABASES, KNOWLEDGBASES, AND ONTOLOGIES

6.3 EXAMPLE COMPUTATIONAL TOXICOLOGY APPLICATIONS

6.4 SUMMARY

REFERENCES AND SUGGESTED READING

NOTE

7 HEMATOTOXICITY: TOXIC EFFECTS ON THE HEMATOPOIETIC SYSTEM

7.1 STRUCTURE AND FUNCTION OF THE HEMATOPOIETIC SYSTEM

7.2 EVALUATION OF THE HEMATOPOEITIC SYSTEM

7.3 MECHANISMS OF HEMATOTOXICITY

7.4 INTERPRETATION OF DRUG (XENOBIOTIC) EFFECTS AND HEMATOPOIETIC RESPONSE PATTERNS

7.5 SUMMARY

REFERENCES AND SUGGESTED READING

8 HEPATOTOXICITY: TOXIC EFFECTS ON THE LIVER

8.1 THE PHYSIOLOGIC AND MORPHOLOGIC BASES OF LIVER INJURY

8.2 TYPES OF LIVER INJURY

8.3 EVALUATION OF LIVER INJURY

8.4 SUMMARY

REFERENCES AND SUGGESTED READING

9 NEPHROTOXICITY: TOXIC EFFECTS ON THE KIDNEY

9.1 RENAL STRUCTURE AND PHYSIOLOGY

9.2 CLASSIFICATIONS OF RENAL INJURY

9.3 ASSESSMENT OF RENAL FUNCTION AND INJURY IN THE CLINIC AND IN IN VIVO ANIMAL MODELS

9.4 IN VITRO MODELS TO STUDY RENAL FUNCTION AND INJURY

9.5 EXAMPLES OF ENVIRONMENTAL, INDUSTRIAL, AND THERAPEUTIC CHEMICALS THAT PRODUCE NEPHROTOXICITY

9.6 SUMMARY

REFERENCES AND SUGGESTED READING

10 NEUROTOXICOLOGY: TOXIC EFFECTS ON THE NERVOUS SYSTEM

10.1 THE NERVOUS SYSTEM

10.2 NEUROTOXICOLOGICAL AGENTS

10.3 ROLE FOR GLIA IN NEUROTOXICITY

10.4 EVALUATION OF NEUROTOXIC INJURY

10.5 SUMMARY

REFERENCES AND SUGGESTED READING

## 11 DERMAL TOXICOLOGY: TOXIC EFFECTS ON THE SKIN

11.1 HISTOLOGY

11.2 FUNCTIONS

11.3 TYPES OF DERMAL TOXICITY

11.4 SUMMARY

REFERENCES AND SUGGESTED READING

## 12 PULMONOTOXICITY: TOXIC EFFECTS IN THE RESPIRATORY SYSTEM

12.1 ANATOMY AND PHYSIOLOGY OF THE RESPIRATORY SYSTEM

12.2 ACUTE RESPONSES OF THE RESPIRATORY SYSTEM TO INJURY

12.3 CHRONIC RESPONSE OF THE RESPIRATORY SYSTEM TO INJURY

12.4 INHALATION TOXICOLOGY OF GASES AND PARTICLES

12.5 EVALUATION OF TOXIC DAMAGE IN THE RESPIRATORY SYSTEM

12.6 SUMMARY

ACKNOWLEDGMENTS

REFERENCES AND SUGGESTED READINGS

## 13 IMMUNOTOXICITY: TOXIC EFFECTS ON THE IMMUNE SYSTEM

13.1 BIOLOGY OF THE IMMUNE RESPONSE

13.2 TYPES OF IMMUNE REACTIONS AND DISORDERS

13.3 CLINICAL TESTS FOR DETECTING IMMUNOTOXICITY

13.4 TESTS FOR DETECTING IMMUNOTOXICITY IN ANIMAL MODELS

13.5 SPECIFIC CHEMICALS THAT ADVERSELY AFFECT THE IMMUNE SYSTEM

13.6 SUMMARY

REFERENCES AND SUGGESTED READING

14 REPRODUCTIVE AND DEVELOPMENTAL TOXICITY: TOXIC EFFECTS ON THE FEMALE AND MALE REPRODUCTIVE TRACTS AND OFFSPRING

14.1 OVERVIEW OF THE REPRODUCTIVE SYSTEM

14.2 PHYSIOLOGY AND HORMONE CONTROL OF THE ADULT FEMALE AND MALE REPRODUCTIVE SYSTEMS

14.3 HUMAN REPRODUCTIVE TOXICANTS

14.4 CURRENT AND NOVEL METHODOLOGIES FOR ASSESSING REPRODUCTIVE TOXICOLOGY

14.5 DEVELOPMENTAL TOXICOLOGY

14.6 PRECONCEPTION EXPOSURE IMPACTS ON DEVELOPMENT

14.7 LIFESTYLE IMPACTS ON EPIGENETICS AND DEVELOPMENT

14.8 OTHER DEVELOPMENTAL TOXICANTS AND MODES OF ACTION

14.9 CURRENT AND NOVEL METHODOLOGIES FOR ASSESSING DEVELOPMENTAL TOXICOLOGY

14.10 SUMMARY

REFERENCES AND SUGGESTED READING

15 MUTAGENESIS AND GENETIC TOXICOLOGY

15.1 FUNDAMENTALS OF CHEMICALLY INDUCED GENETIC DAMAGE

15.2 GENETIC DAMAGE AND ITS IMPACT ON HUMAN DISEASE

15.3 GENETIC TOXICOLOGY TESTS

15.4 HUMAN BIOMONITORING

15.5 REGULATORY USE OF GENETIC  
TOXICOLOGY DATA

15.6 PROMISING NEW APPROACHES

15.7 SUMMARY

REFERENCES AND SUGGESTED READING

## 16 CHEMICAL CARCINOGENESIS

16.1 HISTORY OF CANCER RESEARCH

16.2 NOMENCLATURE AND DEFINITIONS OF  
NEOPLASIA

16.3 CLASSIFICATION OF CARCINOGENS:  
GENOTOXIC VERSUS NONGENOTOXIC

16.4 MULTISTAGE CARCINOGENESIS

16.5 PROTO-ONCOGENES AND TUMOR  
SUPPRESSOR GENES

16.6 POLYMORPHISM IN CARCINOGENESIS

16.7 WELL-KNOWN CLASSES OF CHEMICAL  
CARCINOGENS

16.8 NONGENOTOXIC (EPIGENETIC)  
CARCINOGENS

16.9 THE HALLMARKS OF CANCER

16.10 THE MAJOR CAUSES OF HUMAN CANCER

16.11 CHEMOPREVENTION

16.12 TEST SYSTEMS FOR CARCINOGENICITY  
ASSESSMENT

16.13 CLASSIFICATION OF THE CARCINOGENIC  
RISK FOR HUMANS

16.14 SUMMARY

REFERENCES AND SUGGESTED READING



## 17 PROPERTIES AND EFFECTS OF METALS

17.1 BASIC CHARACTERISTICS OF METALS

17.2 GENERAL PROPERTIES OF ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION OF METALS

17.3 BIOMARKERS

17.4 GENERAL MECHANISMS OF TOXICITY

17.5 ESSENTIALITY VERSUS TOXIC EFFECTS

17.6 TOXICOLOGY OF SPECIFIC METALS

17.7 SUMMARY

REFERENCES AND SUGGESTED READING

NOTE

## 18 PESTICIDES

18.1 PESTICIDE CLASSES AND REGULATIONS

18.2 ORGANOPHOSPHATE AND CARBAMATE INSECTICIDES

18.3 ORGANOCHLORINE INSECTICIDES

18.4 INSECTICIDES OF BIOLOGICAL ORIGIN

18.5 HERBICIDES

18.6 FUNGICIDES

18.7 RODENTICIDES

18.8 FUMIGANTS

18.9 SUMMARY

REFERENCES AND SUGGESTED READING

## 19 PROPERTIES AND TOXICOLOGY OF ORGANIC SOLVENTS AND SOLVENT-LIKE CHEMICALS

19.1 GENERAL CONCEPTS

19.2 EXPOSURE POTENTIAL AND TOXICOKINETICS

19.3 REGULATION OF SOLVENTS EXPOSURE  
POTENTIAL

19.4 REVIEW OF SOLVENT EFFECTS AND  
TARGET ORGAN SYSTEMS

19.5 TOXIC PROPERTIES OF REPRESENTATIVE  
ORGANIC SOLVENTS

19.6 TOXIC PROPERTIES OF HALOGENATED  
SOLVENTS

19.7 TOXIC PROPERTIES OF HYDROXYLATED  
AND OXGENATED SOLVENTS

19.8 TOXIC PROPERTIES OF ALDEHYDES,  
KETONES, AND CARBOXYLIC ACIDS

19.9 TOXIC PROPERTIES OF REPRESENTATIVE  
ESTERS, ETHERS, AND EPOXIDES

19.10 TOXIC PROPERTIES OF REPRESENTATIVE  
NITROGEN-CONTAINING SOLVENTS

19.11 TOXIC PROPERTIES OF SULFUR-  
CONTAINING SOLVENTS

19.12 SUMMARY

REFERENCES AND SUGGESTED READING

20 NANOTOXICOLOGY

20.1 CLASSIFICATION OF NANOMATERIALS AND  
THEIR POTENTIAL APPLICATIONS

20.2 UNIQUE CHALLENGES IN STUDYING  
NANOTOXICOLOGY

20.3 HUMAN NANOTOXICOLOGY

20.4 ENVIRONMENTAL NANOTOXICOLOGY

20.5 MECHANISMS OF TOXICITY (MODES OF  
ACTION)

20.6 SUMMARY

REFERECES AND SUGGESTED READING

## 21 INSIGHTS INTO EPIDEMIOLOGY

21.1 SOME DEFINITIONS AND BASIC PRINCIPLES

21.2 DISEASE FREQUENCY MEASURES USED IN EPIDEMIOLOGY

21.3 STUDY DESIGNS USED IN EPIDEMIOLOGY

21.4 META-ANALYSES

21.5 INTERPRETATION OF EPIDEMIOLOGIC RESULTS

21.6 SUMMARY

REFERENCES AND SUGGESTED READING

NOTES

## 22 OCCUPATIONAL AND ENVIRONMENTAL HEALTH

22.1 HISTORY OF OCCUPATIONAL HEALTH

22.2 DEFINITION AND SCOPE

22.3 DATA SOURCES AND THE BURDEN OF OCCUPATIONAL AND ENVIRONMENTAL ILLNESS AND INJURY

22.4 CHARACTERISTICS OF OCCUPATIONAL ILLNESS

22.5 PREVENTION GOALS

22.6 ACTIVITIES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH SPECIALISTS

22.7 THE MULTIDISCIPLINARY APPROACH TO WORKERS' HEALTH

22.8 LEGAL AND REGULATORY ISSUES RELEVANT TO OCCUPATIONAL AND ENVIRONMENTAL HEALTH

22.9 OCCUPATIONAL EXPOSURE LIMITS

22.10 ETHICAL CONSIDERATIONS FOR THE OCCUPATIONAL AND ENVIRONMENTAL HEALTH

PROFESSIONAL

22.11 SUMMARY

ACKNOWLEDGMENT

REFERENCES AND SUGGESTED READING

NOTE

## 23 HUMAN HEALTH RISK ASSESSMENT

23.1 RISK ASSESSMENT BASICS

23.2 HAZARD IDENTIFICATION

23.3 DOSE-RESPONSE ASSESSMENT

23.4 EXPOSURE ASSESSMENT: EXPOSURE  
PATHWAYS AND RESULTING DOSAGES

23.5 RISK CHARACTERIZATION

23.6 PROBABILISTIC VERSUS DETERMINISTIC  
RISK ASSESSMENTS

23.7 EVALUATING RISK FROM CHEMICAL  
MIXTURES

23.8 COMPARATIVE RISK ANALYSIS

23.9 RISK COMMUNICATION

23.10 SUMMARY

REFERENCES AND SUGGESTED READING

## 24 ECOLOGICAL RISK ASSESSMENT\*

24.1 BASIC STEPS OF ECOLOGICAL RISK  
ASSESSMENT

24.2 HABITAT TYPES OFTEN INVOLVED IN ERA

24.3 SELECTION OF RECEPTORS AND THEIR  
REPRESENTATION IN THE ERA

24.4 TOXICITY VALUES

24.5 EXPOSURE ASSESSMENT

24.6 RISK ESTIMATION

[24.7 ECOLOGICAL RISK ASSESSMENT PROCESS](#)

[24.8 SUMMARY](#)

[REFERENCES AND SUGGESTED READING](#)

[NOTE](#)

[25 THE DILEMMA OF SELECTING SAFE EXPOSURE VALUES](#)

[25.1 FACTORS PRODUCING VARIATIONS IN SAFE EXPOSURE VALUES](#)

[25.2 THE VARIATIONS IN HAZARD ASSESSMENT CONCLUSIONS](#)

[25.3 VARIATIONS IN OCCUPATIONAL EXPOSURE LIMITS \(OEL\)](#)

[25.4 VARIATIONS IN ENVIRONMENTAL EXPOSURE LIMITS](#)

[25.5 EXPOSURE LIMITS AND THE COURTS](#)

[25.6 SUMMARY](#)

[REFERENCES AND SUGGESTED READING](#)

[NOTES](#)

[INDEX](#)

[End User License Agreement](#)

## **List of Tables**

Chapter 1

[TABLE 1.1 Examples Showing a NOAEL or LOAEL May Change with Exposure Duratio...](#)

[TABLE 1.2 Some of the Advantages and Disadvantages of Toxicity Data by Categ...](#)

[TABLE 1.3 Cross-Matching Exercise: Comparative Acutely Lethal Doses](#)



[TABLE 1.4 Cross-Matching Exercise: Occupational Exposure Limits—Aspirin and ...](#)

[TABLE 1.5 A Relative Ranking System for Categorization of the Acute Toxicity...](#)

[TABLE 1.6 Oral LD<sub>50</sub> Data for Chloroform](#)

[TABLE 1.7 Chloroform Toxicity: Inhalation Studies](#)

[TABLE 1.8 Target Organ Comparison of Tumors Induced in Chronic Cancer Bioass...](#)

[TABLE 1.9 Effect of Route of Administration on Response \(LD<sub>50</sub>\).](#)

[TABLE 1.10 Chemical Interactions with Ethanol](#)

[TABLE 1.11 Aquatic Toxicity Interactions between Ammonia and Other Chemicals...](#)

[TABLE 1.12 Pharmacogenetic Differences in Humans](#)

## Chapter 2

[\*\*TABLE 2.1 Toxic Metabolites Formed During the Metabolism of Xenobiotics\*\*](#)

[TABLE 2.2 Cytochrome P450 Catalyzed Oxidation Reactions](#)

[TABLE 2.3 Notable Xenobiotic Substrates of Cytochrome P450s](#)

[TABLE 2.4 Examples<sup>a</sup> of Clinical Inhibitors<sup>b</sup> of Cytochrome P450s](#)

[TABLE 2.5 Xenobiotics Forming Inhibitory Adducts with Cytochrome P450s](#)

[TABLE 2.6 Cytochrome P450-Selective Reactions](#)

[TABLE 2.7 \*\*Xenobiotics Metabolized to Glucuronides\*\*](#)

[TABLE 2.8 Drugs and Endogenous Compounds Metabolized to Sulfate Conjugates](#)

[TABLE 2.9 Methyltransferase Nomenclature and Characteristics](#)

[TABLE 2.10 Components of Four Cytochrome P450 Induction Pathways](#)

[TABLE 2.11 Cytochrome P450 Inducers](#)

[TABLE 2.12 Induction-Related Enhanced Drug Metabolism in Human](#)

Chapter 3

[TABLE 3.1 “Typical” Physiological Parameters for PBPK Models](#)

[TABLE 3.2 Comparison of \*In Vitro\*-to-\*In Vivo\* Extrapolation Modeling Results w...](#)

Chapter 4

[TABLE 4.1 \*\*Common Acronyms for Regulations and Regulatory Agencies\*\*](#)

[TABLE 4.2 \*\*Highlights of FDA, EPA, and OECD Good Laboratory Practice regulati...\*\*](#)

[TABLE 4.3 Testing Requirements for Conventional Chemical Pesticides](#)

[TABLE 4.4 Testing Requirements for Direct Food Additives Based on Concern Le...](#)

[TABLE 4.5 \*\*ICH Safety Testing Guidelines\*\*](#)

[TABLE 4.6 \*\*Studies Required for Approval of a Device\*\*](#)

[TABLE 4.7 Requirements for Mammalian Toxicity Testing Under REACH](#)

[TABLE 4.8 Schedule Requirements for Notification to Canadian Environmental P...](#)

[TABLE 4.9 Serum Chemistries and the Organ/Physiological State that are Refle...](#)

[TABLE 4.10 List of Testing Guidelines for Various Mammalian Study Designs](#)

[TABLE 4.11 GHS Categories for Acute Toxicity](#)

[TABLE 4.12 Classifications of Acute Oral Toxicity Under GHS and EPA](#)

## Chapter 5

[\*\*TABLE 5.1 Relevant Legislation and Administrative Efforts related to Alterna...\*\*](#)

[\*\*TABLE 5.2 Non-Governmental Organizations involved in Alternative Testing Met...\*\*](#)

[\*\*TABLE 5.3 Regulatory Agencies Involved in Development and Validation of Alte...\*\*](#)

## Chapter 6

[\*\*TABLE 6.1 Typical Types of Signal Readouts Used in HTS Assays\*\*](#)

## Chapter 7

[\*\*TABLE 7.1 Classes of Agents Causing Injury to Hematopoietic Cells\*\*](#)

[\*\*TABLE 7.2 Agents Causing Injury to Circulating Cells\*\*](#)

[\*\*TABLE 7.3 Expected Pattern of Findings Based on Type of Injury or Damage\*\*](#)

[TABLE 7.4 Agents Causing Heinz Body Anemia in Animals](#)

[TABLE 7.5 Patterns of Effects in Blood and Bone Marrow](#)

[TABLE 7.6 Causes of Hemolysis](#)

[TABLE 7.7 Main Features of Intravascular and Extravascular Hemolysis](#)

[TABLE 7.8 Causes of Platelet Count Decreases](#)

## Chapter 8

[TABLE 8.1 Drugs and Chemicals that Produce Zonal Hepatic Necrosis](#)

[TABLE 8.2 Drugs and Chemicals that Produce Fatty Liver](#)

[TABLE 8.3 Drugs and Chemicals that Produce Cholestasis](#)

[TABLE 8.4 Serum Enzyme Indicators of Hepatotoxicity](#)

## Chapter 9

[TABLE 9.1 Filtration and Reabsorption of Water and Electrolytes by the Human...](#)

[TABLE 9.2 Differential Morphology, Biochemistry, and Physiology of Selected ...](#)

[TABLE 9.3 Basic Characteristics of Major Plasma Membrane Transporters in Hum...](#)

[TABLE 9.4 Factors Influencing Susceptibility of Kidneys to Chemically Induce...](#)

[TABLE 9.5 Urinary Enzymes and Proteins Released or Upregulated and Secreted ...](#)

[TABLE 9.6 Experimental Protocols Performed with Primary Cultures for Toxicol...](#)

[TABLE 9.7 Selected Immortalized, Continuous Renal Cell Lines that are Commer...](#)

## Chapter 11

[TABLE 11.1 Defense Roles of the Skin](#)

[TABLE 11.2 Potential Inducers of Irritant Contact Dermatitis](#)

[TABLE 11.3 Commonly Encountered Contact Allergens](#)

## Chapter 12

[TABLE 12.1 Major Toxic Gases and Characteristics](#)

[TABLE 12.2 Definition and Interpretation of Common Pulmonary Function Values](#)

## Chapter 13

[TABLE 13.1 Major Cytokines and Their Functions](#)

[TABLE 13.2 Examples of Agents Used for Immune Challenge in Host Resistance T...](#)

[TABLE 13.3 Examples of Agents that Produce Dermal Contact Sensitivity](#)

[TABLE 13.4 Examples of Agents that Produce Respiratory Allergy](#)

[TABLE 13.5 Examples of Agents Associated with Autoimmune Disease](#)

## Chapter 15

[TABLE 15.1 Types of DNA Damage and Examples of Chemical/Physical Agents that...](#)



[TABLE 15.2 Commonly Used Ames Test Strains, the Types of Mutation Detected, ...](#)

[TABLE 15.3 Types of Genetic Damage Detected in the Different Standard Geneti...](#)

## Chapter 16

[TABLE 16.1 Selected Historical Events in Chemical and Physical Carcinogenesi...](#)

[TABLE 16.2 Definitions of Neoplasia](#)

[TABLE 16.3 Nomenclature](#)

[TABLE 16.4 Characteristics of Genotoxic and Nongenotoxic Carcinogens](#)

[TABLE 16.5 Characteristics of DNA Reactive/Genotoxic Carcinogens](#)

[TABLE 16.6 DNA Base Targets for Possible Carcinogen Adduct Formation by Alky...](#)

[TABLE 16.7 Characteristics of Multistep Process of Carcinogenesis](#)

[TABLE 16.8 DNA Repair Pathways](#)

[TABLE 16.9 Common Characteristics of Proto-Oncogenes, Oncogenes, and Tumor S...](#)

[TABLE 16.10 Oncogenes and Tumor Site Association](#)

[TABLE 16.11 Examples of Tumor Suppressor Genes and Tumor Site Association](#)

[TABLE 16.12 Carcinogen Exposure and Cancer Risk in Humans](#)

[TABLE 16.13 Carcinogenicity of Metals](#)

[TABLE 16.14 Modes of Action for Selected Nongenotoxic Chemical Carcinogens](#)

[TABLE 16.15 Examples of Reactive Oxygen Species](#)

[TABLE 16.16 Reactive Oxygen Species Generation and Removal in the Cell](#)

[TABLE 16.17 Carcinogenic Factors Associated with Lifestyle](#)

[TABLE 16.18 Human Carcinogenic Chemicals Associated with Medical Therapy & D...](#)

[TABLE 16.19 Carcinogenic Factors Viruses, Bacteria, and Parasites](#)

[TABLE 16.20 Occupational Human Carcinogens](#)

[TABLE 16.21 Cancer Chemopreventive Agents](#)

[TABLE 16.22 Assays for the Identification of Carcinogenic Potential](#)

[TABLE 16.23 Short-Term Tests for Mutagenicity](#)

[TABLE 16.24 Animal Models of Neoplastic Development](#)

[TABLE 16.25 IARC Classification of the Evaluation of Carcinogenicity for Hum...](#)

[TABLE 16.26 USEPA Cancer Guidelines Descriptors](#)

[TABLE 16.27 Mode of Action Definitions and Framework](#)

## Chapter 17

[TABLE 17.1 Typical Environmental Concentrations of Metals](#)

[TABLE 17.2 Occupational Exposure Levels for Metals](#)

[TABLE 17.3 Health-Based Oral Intake Levels for Metals](#)

## Chapter 18

[TABLE 18.1 Classes of Pesticides and Their Targets](#)

[TABLE 18.2 Most Commonly Used Pesticides in the United States—2012](#)

[TABLE 18.3 Signs and Symptoms of Organophosphate Intoxication](#)

[TABLE 18.4 2020 ACGIH<sup>®</sup> \*\*Biological Exposure Indices \(BEI<sup>®</sup>\) for Various P...\*\*](#)

## Chapter 19

[TABLE 19.1 Physical/Chemical Properties of Representative Solvents and Relat...](#)

[TABLE 19.2 Concentration Ranges for Selected Solvents and Related Substances...](#)

[TABLE 19.3 ACGIH Biological Exposure Index \(BEI\) for Selected Solvents and R...](#)

[TABLE 19.4 Occupational Exposure Limits for Selected Solvents and Related Ma...](#)

[TABLE 19.5 Occupational Exposure Guideline Definitions](#)

[TABLE 19.6 Relative CNS-Depressant and Irritant Potency of Selected Organic ...](#)

[TABLE 19.7 Dose-Response Relationship for Formaldehyde Inhalation in Humans...](#)

[TABLE 19.8 Relative Base Strength of the Amines](#)

[TABLE 19.9 Relative Toxicity of the Amines](#)

## Chapter 20

[TABLE 20.1 \*\*Predicted Environmental Concentrations of Engineered Nanomaterial...\*\*](#)

[TABLE 20.2 Possible Mechanisms of Toxicity for Nanomaterials \(Including both...](#)

## Chapter 21

[TABLE 21.1 Sample Definitions of Epidemiology](#)

[TABLE 21.2 Overview of Common Disease Frequency Measures and Forms](#)

[TABLE 21.3 Summary of Key Parameters of Observational Study Designs](#)

[TABLE 21.4 Hill's Criteria for Causation](#)

## Chapter 22

[\*\*TABLE 22.1 Examples of Organ System, Occupation or Setting, Specific Exposur...\*\*](#)

[TABLE 22.2 Hierarchy of Control](#)

[TABLE 22.3 Examples of Occupational Health Staff Structure in Manufacturing,...](#)

[TABLE 22.4 Evaluation of Health Risk from Dust Exposure](#)

[TABLE 22.5 Evaluation of Health Risk from Lifting Task](#)

[TABLE 22.6 Select Occupational Exposure Limits by Major \(US\) Organizations](#)

## Chapter 23

[TABLE 23.1 Expected Risk \(Cancer Incidence\) Calculated by Three Models When ...](#)

[TABLE 23.2 Proposed Toxic Equivalency Factors \(TEFs\) for PCB Congeners Relat...](#)

[TABLE 23.3 Cancer Risks for Indoor Air Exposures to volatile organic compoun...](#)

[TABLE 23.4 Cancer Risks for Household Exposures to Pesticides in the Lower R...](#)

[TABLE 23.5 Estimated Average Loss of Life Expectancy from Various Risks, Act...](#)

[TABLE 23.6 Examples of Risk Communication Problems](#)

## Chapter 25

[TABLE 25.1 Issues Creating Variations in the Exposure Limits Derived by Diff...](#)

[TABLE 25.2 Ruden's Summary Observations Based on an Analysis of 29 TCE Hazar...](#)

[TABLE 25.3 Recent Hazard Assessments for Glyphosate](#)

[TABLE 25.4 A Comparison of the Glyphosate Hazard Assessments Performed by IA...](#)

[TABLE 25.5 Comparison of Occupational Exposure Limits Set by Different Agenc...](#)

[TABLE 25.6 US EPA and State Derived Drinking Water Criteria for PFOA and PFO...](#)

[TABLE 25.7 The Three Fundamental Components of a Real Risk Factor: and A Com...](#)

## List of Illustrations

### Chapter 1

[FIGURE 1.1 A generic toxicity testing scheme that shows the ways in which a ...](#)

[FIGURE 1.2 A timeline showing the progression of toxicity testing for a chem...](#)



[FIGURE 1.3 Acute lethal dose comparisons of two substances commonly used by...](#)

[FIGURE 1.4 The dose-response outcome for the therapeutic and toxic effects o...](#)

[FIGURE 1.5 Shows the response for each dose tested \(round closed circles\), w...](#)

[FIGURE 1.6 A schematic representation for a therapeutic drug showing how phy...](#)

[FIGURE 1.7 \(a\) The dose-response curves with log-linear \(1\), sublinear \(2\),...](#)

[FIGURE 1.8 By plotting the cumulative dose-response curves \(log dose\), one c...](#)

[FIGURE 1.9 By plotting or comparing several dose-response curves for a toxic...](#)

[FIGURE 1.10 Graphically demonstrates how the regulatory community develops s...](#)

[FIGURE 1.11 The shape of the dose-response curve is important. By finding th...](#)

[FIGURE 1.12 A simple schematic showing how a mixture formed by combining two...](#)

## Chapter 2

[FIGURE 2.1 Key sites and effectors of xenobiotic absorption.](#)

[FIGURE 2.2 The interrelationship of xenobiotic absorption \(A\), metabolism \(M...](#)

[FIGURE 2.3 Major routes of xenobiotic metabolism simplified into the generat...](#)

[FIGURE 2.4 Changes in chemical reactivity and excretability with metabolism....](#)

[FIGURE 2.5 Hepatocyte xenobiotic metabolism and excretion.](#)

[FIGURE 2.6 Multiple site and multiple enzyme participation in metabolism.](#)

[FIGURE 2.7 Activity-decreasing polymorphisms and pharmacokinetics.](#)

[FIGURE 2.8 CYP2D6 polymorphism considerations.](#)

[FIGURE 2.9 Competitive, noncompetitive, and mechanism-based P450 inhibition....](#)

[FIGURE 2.10 Commonality of glucuronidation and sulfation.](#)

[FIGURE 2.11 Acetaminophen metabolism and toxicity.](#)

[FIGURE 2.12 Activity and mRNA changes with inducer exposure.](#)

[FIGURE 2.13 Xenobiotic metabolizing enzyme induction.](#)

[FIGURE 2.14 Examples of the diversity of pregnane X receptor \(PXR\) agonists....](#)

[FIGURE 2.15 Examples of the planar nature of Aromatic hydrocarbon receptor \(...\)](#)

[FIGURE 2.16 Processes linked to the renal elimination of xenobiotics.](#)

[FIGURE 2.17 Transporter involvement in renal xenobiotic excretion.](#)

## Chapter 3

[FIGURE 3.1 Diagram of a physiologically based pharmacokinetic \(PBPK\) model f...](#)

[FIGURE 3.2 Illustration of a zero-order reaction.](#)

[FIGURE 3.3 Illustration of a first-order reaction.](#)

[FIGURE 3.4 Illustration of a capacity-limited reaction.](#)

[FIGURE 3.5 PBPK modeling approach.](#)

[FIGURE 3.6 Blood concentrations of isopropanol \(IPA\) and its metabolite acet...](#)

[FIGURE 3.7 Blood concentrations of perchloroethylene \(PERC\) and its primary...](#)

[FIGURE 3.8 Paraoxon AUC distribution for the total population \(Case 3, inclu...](#)

[FIGURE 3.9 Model structure for DBP kinetics in the pregnant rat. Dashed arro...](#)

[FIGURE 3.10 Model parameterization and validation for the adult male, pregna...](#)

[FIGURE 3.11 MBP in maternal plasma, fetal plasma, and fetal testes after the...](#)

[FIGURE 3.12 DBP dose-response: Predicted average daily concentration of MBP ...](#)

## Chapter 4

[FIGURE 4.1 Organization of the US EPA office of chemical safety and pollutio...](#)

[FIGURE 4.2 Concern levels for direct food additives based on structure and e...](#)

## Chapter 5

[FIGURE 5.1 Immortal HeLa cells grown in cell culture medium, 24 h after thaw...](#)

[FIGURE 5.2 Light microscopy images of spheroid cultures of Rainbow Trout Liv...](#)

[FIGURE 5.3 3-D breast cell organoids in culture derived from an individual h...](#)

[FIGURE 5.4 H&E staining of the ALI airway tissue models. The luminal surface...](#)

[FIGURE 5.5 Illustration of human-on-a-chip designed with 11 human organ equi...](#)

[FIGURE 5.6 \*Daphnia magna\* neonate \(less than 24 h old\). This freshwater inver...](#)

[FIGURE 5.7 Mixed-stage population of \*Caenorhabditis elegans\* in 2  \$\mu\$ l liquid c...](#)

[FIGURE 5.8 Example of read-across analysis used to interpret and extrapolate...](#)

[FIGURE 5.9 \(a\) Generalized adverse outcome pathway \(AOP\) schematic. A molecu...](#)

## Chapter 6

[FIGURE 6.1 Chemical structure of Atrazine.](#)

[FIGURE 6.2 A large-scale robotic screening system in use at the NIH Chemical...](#)

[FIGURE 6.3 ToxPi signature for developmental vascular toxicity based on the ...](#)

[FIGURE 6.4 Vascular disruption potential of 38 ToxCast chemicals selected to...](#)

[FIGURE 6.5 ToxPi prioritization of all 309 ToxCast Phase I chemicals. The To...](#)

[FIGURE 6.6 Comparing exposure to AEDs and existing animal data. A conceptual...](#)

[FIGURE 6.7 Summary of linkages between types of computational toxicology dat...](#)

## Chapter 7

[FIGURE 7.1 Diagrammatical representation of the vascular supply of the bone ...](#)

[FIGURE 7.2 Representation of the maturation progression of the multiple cell...](#)

## Chapter 8

[\*\*FIGURE 8.1 The liver maintains a unique position within the circulatory syst...\*\*](#)

[FIGURE 8.2 Hepatic architecture, showing arrangement of blood vessels and li...](#)

[FIGURE 8.3 Structure of the liver acinus. THV, terminal hepatic vein; PS, po...](#)

[FIGURE 8.4 Liver section from mouse given a toxic dose of acetaminophen show...](#)

## Chapter 9

[FIGURE 9.1 Schematic of the basic functional unit of the kidneys, the nephro...](#)

[FIGURE 9.2 Modes by which plasma membrane transport determines drug disposit...](#)

[FIGURE 9.3 Coupling of primary, secondary, and tertiary active transport sys...](#)

[FIGURE 9.4 Generalized scheme of responses of renal cells to nephrotoxicant ...](#)

[FIGURE 9.5 Scheme of biochemical mechanisms by which nephrotoxic chemicals a...](#)

[FIGURE 9.6 Variation of serum creatinine \(SCr\) and blood urea nitrogen \(BUN\)...](#)

[FIGURE 9.7 Chemical structures of nephrotoxic cysteine conjugates of halogen...](#)



[FIGURE 9.8 Experimental approaches to validation of the bioactivation pathwa...](#)

[FIGURE 9.9 Metabolic pathways for detoxification and bioactivation of acetam...](#)

[FIGURE 9.10 Comparison between chemical structures of penicillins and cephal...](#)

[FIGURE 9.11 Proposed bioactivation mechanisms for cephaloridine \(CPH\). The f...](#)

## Chapter 10

[FIGURE 10.1 Superficial structures of the human brain.](#)

[FIGURE 10.2 Coronal aspect of the human brain.](#)

[FIGURE 10.3 Diagram of components involved in the neuronal action potential....](#)

[FIGURE 10.4 Sites of neurotoxicological effects.](#)

[FIGURE 10.5 Sites of altered neurotransmission following toxic insult. Sites...](#)

## Chapter 11

[FIGURE 11.1 Diagram of a cross-section of skin.](#)

[FIGURE 11.2 Allergic contact dermatitis caused by neomycin \(a\) on the leg in...](#)

[FIGURE 11.3 Diagnostic patch testing.](#)

[FIGURE 11.4 Hyperpigmented macules coalescing into patches on the left dorsa...](#)

[FIGURE 11.5 Photopatch testing with two identical patches. The left patch wa...](#)

## Chapter 12

[FIGURE 12.1 Frontal view of the skull showing frontal, maxillary, and ethmoi...](#)

[FIGURE 12.2 Sagittal view of the skull, showing nasal turbinates and sphenoi...](#)

[FIGURE 12.3 Schematic representation of the subdivisions of the conducting a...](#)

[FIGURE 12.4 Principal sites of particle clearance in the lungs.](#)

## Chapter 13

[FIGURE 13.1 Light and heavy chain structure of IgG. IgG illustrates the basi...](#)

## Chapter 14

[FIGURE 14.1 The female reproductive system anatomy.](#)

[FIGURE 14.2 The male reproductive system anatomy.](#)

[FIGURE 14.3 Ovarian folliculogenesis and oogenesis.](#)

[FIGURE 14.4 The ovarian steroidogenesis pathway.](#)

[FIGURE 14.5 An overview of human spermatogenesis.](#)

[FIGURE 14.6 The female HPG axis.](#)

[FIGURE 14.7 The male HPG axis.](#)

[FIGURE 14.8 Timeline of female reproductive system development.](#)

[FIGURE 14.9 Graphic illustrating potential windows of susceptibility to deve...](#)

## Chapter 15